Oppenheimer & Co. Inc. Grows Stock Position in Zoetis Inc. $ZTS

Oppenheimer & Co. Inc. raised its stake in shares of Zoetis Inc. (NYSE:ZTS) by 15.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 104,946 shares of the company’s stock after buying an additional 13,764 shares during the period. Oppenheimer & Co. Inc.’s holdings in Zoetis were worth $13,204,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. increased its stake in shares of Zoetis by 12.9% in the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after purchasing an additional 5,474,210 shares in the last quarter. Nordea Investment Management AB increased its stake in shares of Zoetis by 79.2% in the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after purchasing an additional 2,179,578 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Zoetis by 14.6% in the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,312,779 shares of the company’s stock valued at $631,046,000 after purchasing an additional 550,859 shares in the last quarter. Alliancebernstein L.P. increased its stake in shares of Zoetis by 13.3% in the 3rd quarter. Alliancebernstein L.P. now owns 4,241,357 shares of the company’s stock valued at $620,595,000 after purchasing an additional 496,320 shares in the last quarter. Finally, Fundsmith LLP increased its stake in shares of Zoetis by 25.3% in the 3rd quarter. Fundsmith LLP now owns 3,615,131 shares of the company’s stock valued at $528,966,000 after purchasing an additional 730,300 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

NYSE:ZTS opened at $115.10 on Friday. Zoetis Inc. has a 12 month low of $112.97 and a 12 month high of $172.23. The stock has a 50 day moving average of $119.93 and a two-hundred day moving average of $124.79. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The firm has a market cap of $48.42 billion, a P/E ratio of 19.12, a price-to-earnings-growth ratio of 1.75 and a beta of 0.98.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. During the same period in the previous year, the business earned $1.40 EPS. Zoetis’s quarterly revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, analysts expect that Zoetis Inc. will post 7.02 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 1.8%. The ex-dividend date is Monday, April 20th. Zoetis’s payout ratio is 35.22%.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. UBS Group cut their price target on Zoetis from $136.00 to $130.00 and set a “neutral” rating for the company in a research note on Tuesday. Bank of America lifted their price target on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Friday, February 13th. BTIG Research restated a “buy” rating and issued a $160.00 price target on shares of Zoetis in a research note on Thursday, February 26th. William Blair restated an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Finally, Piper Sandler restated a “neutral” rating and issued a $135.00 price target (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $151.75.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.